2019³â Á¦ 15Â÷ ´ëÇѹé½ÅÇÐȸ Ãß°èÇмú´ëȸ : 2019-10-11±³À°ÀÏÀÚ : 2019-10-11
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç
±³À°ÁÖÁ¦ :
2019³â Á¦ 15Â÷ ´ëÇѹé½ÅÇÐȸ Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇѹé½ÅÇÐȸ
´ã´çÀÚ : ÀÌ¿µ¼ö
¿¬¶ôó : 02-2258-7472
À̸ÞÀÏ :
office@korvac.org ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, À̺ñÀÎÈÄ°ú, °¡Á¤ÀÇÇаú¿¹¹æÀÇÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í ȸ¿ø »çÀüµî·Ï µî±Þº° 3¸¸¿ø, 5¸¸¿ø, ºñȸ¿ø »çÀüµî·Ï 8¸¸¿ø ȸ¿ø ÇöÀåµî·Ï µî±Þº° 5¸¸¿ø, 7¸¸¿ø, ºñȸ¿ø ÇöÀåµî·Ï 10¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 08:50~09:00 Opening °ÁøÇÑ(°¡Å縯ÀÇ´ë ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 09:00~09:20 Herpes zoster ¹Ú¼±Èñ(°¡Å縯ÀÇ´ë °¨¿°³»°ú)
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 09:20~09:40 Hepatitis A ±èÀǼ®(¼¿ïÀÇ´ë °¨¿°³»°ú)
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 09:40~10:10 Development of Plant-Derived Human Vaccine: Candidates for Influenza ½Éº´½Ä(ÁöÇ÷¯½º »ý¸í°úÇÐ)
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 10:10~10:40 World¡¯s First Approved Plant-Derived Subunit Vaccine against Swine Fever Virus ¼ÕÀºÁÖ(¹ÙÀÌ¿À¾Û)
ÈÞ½Ä 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 10:40~10:50 Coffee break ()
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 10:50~11:30 Recent Epidemiology of Pertussis in Japan and next Challenge Tomimasa Sunagawa(National Institute of Infectious Diseases, Japan)
±âŸ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 11:30~12:00 ´ëÇѹé½ÅÇÐȸ ÃÑȸ ()
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 12:00~13:00 Burden of Pneumococcal Disease and Importance of Pneumococcal Vaccination in adults ÀÌÀç°©(ÇѸ²ÀÇ´ë °¨¿°³»°ú)
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 13:00~14:00 Oral Presentation ȲÀÀ¼ö(¼¿ï´ë ¹Ì»ý¹°Çб³½Ç)
ÈÞ½Ä 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 14:00~14:30 Poster round & Coffee Break ()
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 14:30~14:55 Current Strategies of National Vaccine Injury Compensation Programs in Korea ±èÁ¾Èñ(Áúº´°ü¸®º»ºÎ)
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 14:55~15:20 Introduction of Adverse Drug Reaction Relief System in Korea: Examples of Vaccine Cases ÃÖ¹®Áø(Çѱ¹ÀǾàÇ°¾ÈÀü°ü¸®¿ø)
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 15:20~15:45 Vaccines in Cancer Patients undergoing Chemotherapy °Ã¶ÀÎ(¼º±Õ°üÀÇ´ë °¨¿°³»°ú)
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 15:45~16:10 Vaccines in Solid Organ Transplantation Recipients ÇÑ»óÈÆ(¿¬¼¼ÀÇ´ë °¨¿°³»°ú)
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 16:10~16:35 Vaccines in Patients with Rheumatologic Diseases ¼ÛÁØ¿µ(°í·ÁÀÇ´ë °¨¿°³»°ú)
±³À°½Ã°£ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 16:35~17:00 Vaccines in Medical Personnel ÃÖÈñÁ¤(ÀÌÈÀÇ´ë °¨¿°³»°ú)
±âŸ 10-11 °¡Å縯´ëÇб³ ÀÇ»ý¸í»ê¾÷¿¬±¸¿ø 2Ãþ ´ë°´ç 17:00~17:10 Closing ±è¿ìÁÖ(°í·ÁÀÇ´ë °¨¿°³»°ú)